Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
November 28, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 21, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
November 16, 2022 07:00 ET
|
Athira Pharma, Inc.
Fosgonimeton treatment showed results suggestive of neuroprotection and potential disease modification in models of Parkinson’s disease Small molecule positive modulators of HGF/MET improved symptoms...
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
November 10, 2022 16:05 ET
|
Athira Pharma, Inc.
Independent, unblinded, interim efficacy and futility analysis of Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer’s disease patients supports potential clinically meaningful activity of...
Athira Pharma to Present at Stifel 2022 Healthcare Conference
November 09, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
November 07, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
October 17, 2022 07:00 ET
|
Athira Pharma, Inc.
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk Updated study well powered for primary endpoint with addition of fewer...
Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
September 06, 2022 07:00 ET
|
Athira Pharma, Inc.
Adapting study to focus on the evaluation of fosgonimeton monotherapy Conducting an independent, unblinded interim analysis to confirm sample size for primary endpoint of Global Statistical Test...
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
August 15, 2022 16:05 ET
|
Athira Pharma, Inc.
Presented clinical and preclinical data at Alzheimer’s Association International Conference 2022 Strong balance sheet to support clinical development pipeline BOTHELL, Wash., Aug. 15, 2022 (GLOBE...
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022
August 03, 2022 11:28 ET
|
Athira Pharma, Inc.
Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of independence Plasma biomarker data in a...